Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated May 12, 2026. The report serves as a vehicle to disseminate a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Marseille, France, and files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text contains only the cover page and signature block of the Form 6-K. It does not include the content of the referenced press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as no financial data or operational updates are included in the excerpt.
Guidance, Outlook, and Risks
The filing references a press release but does not contain its text. Therefore, no guidance, outlook, management commentary, risks, contingencies, or unusual items are disclosed in the provided content.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated May 12, 2026) to understand the specific event triggering this filing.
- Confirm whether the press release contains updated clinical trial data, regulatory milestones, or financial guidance.
- Review the most recent Form 20-F or quarterly reports for the latest audited financial metrics, as this 6-K does not contain them.